"We are concerned the data from this open-label global trial has not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design," it said. Today, you can download 7 Best Stocks for the Next 30 Days. This change lagged the S&P 500's daily gain of 0.67%. Elsewhere, the Dow gained 1.6%, while the tech-heavy Nasdaq added 2.71%. "The emerging (WHO) data appears inconsistent, with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of remdesivir," Gilead told Reuters. GILD will be looking to display strength as it nears its next earnings release. Yahoo fa parte del gruppo Verizon Media. The Gilead Sciences Research Scholars Programs provide financial support to junior faculty researchers for a 2-year period. This move lagged the S&P 500's daily gain of 2.02%. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. The Business principal activity is in WHOLESALE OF MEDICINAL AND PHARMACEUTICAL PRODUCTS (WESTERN). You can change your choices at any time by visiting Your Privacy Controls. Each award is funded up to $130,000, to be paid in annual installments of up to $65,000 per year for 2 years. In a blow to one of the few drugs being used to treat people with Covid-19, the WHO said on Thursday its "Solidarity" trial had concluded that remdesivir appeared to have little or no effect on 28-day mortality or length of hospital stays among patients with the respiratory disease. 2020. 333 Lakeside Drive It is also important to note the recent changes to analyst estimates for GILD. The Solidarity trial also evaluated hydroxychloroquine, anti-HIV drug combination lopinavir/ritonavir and interferon, and concluded that they, like remdesivir, did little to help patients survive or leave the hospital more quickly. Gilead Sciences, Inc. / ˈ ɡ ɪ l i ə d /, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs.The company focuses primarily on antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500 In the latest trading session, Gilead Sciences (GILD) closed at $64.51, marking a +0.58% move from the previous day. In April, the top US infectious disease official, Anthony Fauci, predicted remdesivir would become "the standard of care". The company is expected to report EPS of $1.90, up 8.57% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $6.38 billion, up 13.84% from the prior-year quarter. BHD. In the latest trading session, Gilead Sciences (GILD) closed at $65.91, marking a -1.32% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.51%. Read also:WHO study says remdesivir did not cut hospital stay or mortality in Covid-19 patients — FT. © All rights reserved. GILD's industry had an average PEG ratio of 1.69 as of yesterday's close. Remdesivir got emergency use authorization from the US Food and Drug Administration on May 1, and has been authorized for use in several countries. © 2020 Gilead Sciences, Inc. All rights reserved. During the Solidarity study, trials of hydroxychloroquine and lopinavir/ritonavir were stopped in June after they proved ineffective, but the studies of Gilead's drug and interferon continued in more than 500 hospitals and 30 countries. Bhd. For the latest updates on our ongoing response to COVID-19, please click here. To learn more about our products, please see our Medicines page. The Gilead Sciences Research Scholars Programs provide financial support to junior faculty researchers for a 2-year period. Gilead said it was "unclear if any conclusive findings can be drawn" given what it called differences in how the trial was conducted from site to site and between the patients who received the medicine. Coming into today, shares of the HIV and hepatitis C drugmaker had lost 5.82% in the past month. Find contact information for Gilead Sciences, Inc. BACK TO MAIN MENU Company Statements Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network Gilead Sciences Statement on … The American company told Reuters the data appeared inconsistent, the findings were premature and that other studies had validated the drug's benefits. To learn more about our products, please see our Medicines page. Find out more about how we use your information in our Privacy Policy and Cookie Policy. 10 stocks we like better than Gilead Sciences. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. Gilead Sciences was the second-best performing stock in the S&P 500 and was just one of two stocks in the Nasdaq-100 that was trading higher on … +800 120 6236 (toll-free number). WHO chief scientist Soumya Swaminathan said this week the UN health agency was now looking at other, emerging treatment options such as monoclonal anti-bodies, immunomodulators and some newer anti-viral drugs. Each award is funded up to $130,000, to be paid in annual installments of up to $65,000 per year for 2 years. Senators on Trial Diversity, Gilead Sciences Statement on NEJM Publication of Remdesivir Data From NIAID Study, Gilead Sciences Statement on Expanding Global Supply of Investigational Antiviral Remdesivir, Gilead Statement on Complaint Against Federal Government in The Court of Federal Claims, Gilead Sciences Statement on Data From Remdesivir Study in Patients With Severe COVID-19 in China, Gilead Sciences Response to Médecins Sans Frontières, Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation, Gilead Sciences Statement on Ensuring Continued Supply of HIV Medicine Amid Coronavirus Outbreak, Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials, Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents, Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV), Gilead Statement on Commitment to Advancing Descovy for PrEP™ Study in Cisgender Women & Adolescent Females, Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents, Petitions to US Patent and Trademark Office on HIV PrEP Patents, Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy. This industry currently has a Zacks Industry Rank of 187, which puts it in the bottom 27% of all 250+ industries. Meanwhile, the Dow gained 0.57%, and the Nasdaq, a tech-heavy index, added 0.61%. Gilead Sciences Research Scholars Programs. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. The antiviral medication was one of the drugs used to treat US President Donald Trump's coronavirus infection, and has been shown in previous studies to have cut time to recovery, though the European Union is investigating it for possible kidney injury. For the latest updates on our ongoing response to COVID-19, please, Clinical Trials Transparency & Data Sharing Policy, Gilead Sciences Statement on the Solidarity Trial, Statement from Brett Pletcher on Gilead Sciences Settlement Over Charitable Donations, Gilead Remains Committed to Maintaining Advancing Access® Program for HIV Prevention and Treatment Medicines, Gilead Sciences Update on Veklury® (Remdesivir) Manufacturing Network, Gilead Sciences Statement on State Attorneys General Letter on Remdesivir, Gilead Sciences Statement on the Initiation of Clinical Testing of an Inhaled Solution of Remdesivir for Potential Outpatient Treatment of COVID-19, Gilead Sciences Statement on Phase 2/3 Clinical Trial of Remdesivir in Pediatric Patients Hospitalized With COVID-19, Gilead Sciences Statement on Remdesivir Clinical Data, Gilead Sciences Response to U.S. The Business current operating status is live with registered address at HARBOURFRONT TOWER ONE. GILEAD SCIENCES MALAYSIA SDN. The WHO trial's results are yet to be reviewed and were uploaded on the preprint server medRxiv. This change lagged the S&P 500's 0.52% gain on the day. (Oct 15): Gilead Sciences Inc has questioned the findings of a World Health Organization (WHO) study that concluded its Covid-19 drug remdesivir does not help patients who have been admitted to hospital. Eli Lilly and Co said on Tuesday a trial of its Covid-19 antibody treatment had been paused by the US government because of a safety concern.